Taichung, Taiwan

Jang-Chang Lee



 

Average Co-Inventor Count = 16.0

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2013-2015

where 'Filed Patents' based on already Granted Patents

4 patents (USPTO):

Title: The Innovative Contributions of Jang-Chang Lee

Introduction

Jang-Chang Lee is a prominent inventor based in Taichung, Taiwan. He has made significant contributions to the field of anticancer research, holding a total of 4 patents. His work focuses on the development of novel compounds that exhibit promising anticancer activities.

Latest Patents

Among his latest patents, Jang-Chang Lee has developed 2-phenyl-4-quinolones as anticancer agents. This innovative process involves converting 2-aryl-4-quinolones into phosphates by reacting them with tetrabenzyl pyrophosphate to form dibenzyl phosphates. These phosphates are then subjected to hydrogenation, replacing dibenzyl groups with hydrogen, followed by a reaction with Amberlite IR-120 (Naform) to create disodium salts. Preliminary screening results have shown that these phosphates possess significant anti-cancer activity. Additionally, he has synthesized a novel intermediate, 2-selenophene 4-quinolone, along with N,N-dialkylaminoalkyl derivatives of 2-phenyl-4-quinolones, which also exhibited significant anticancer activities.

Career Highlights

Jang-Chang Lee is affiliated with China Medical University, where he continues to advance his research in the field of medicinal chemistry. His innovative approaches and dedication to developing effective anticancer agents have positioned him as a key figure in his field.

Collaborations

He has collaborated with notable colleagues, including Sheng-Chu Kuo and Che-Ming Teng, to further enhance the impact of his research.

Conclusion

Jang-Chang Lee's contributions to anticancer research through his innovative patents and collaborations highlight his commitment to improving cancer treatment options. His work continues to inspire advancements in medicinal chemistry and cancer therapeutics.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…